Results 31 to 40 of about 16,086,300 (146)

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, Volume 209, Issue 3, Page 1230-1238, September 2026.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, Volume 101, Issue 8, Page 1818-1827, August 2026.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023–May 2024).
Natalia Rotter, Markus Raderer, Agnes List, Ferdinand Haslbauer, Olga Saini, Alexander Egle, Teresa Magnes, Michael Leisch, Emine Kaynak, Veronika Buxhofer‐Ausch, Beatrice Casadei, Felix Keil, Holger Rumpold, Georg Hess, Richard Greil, Pier Luigi Zinzani, Thomas Melchardt   +16 more
wiley   +1 more source

ISSP 2000 Germany - Environment II ZUMA report on the German study [PDF]

, 2002
ZUMA erstellt englischsprachige Berichte ueber die Implementation der ISSP-Untersuchungen in Deutschland, um Nutzer aus dem Ausland mit Basisinformationen ueber die einzelnen Untersuchungen zu versorgen.
Harkness, Janet, Stadler, Stefan, Zentrum fuer Umfragen, Methoden und Analysen -ZUMA-, Mannheim (Germany), Scholz, Evi   +3 more
core   +2 more sources

Dual‐Targeting, Hybrid Antifungal Agents Targeting Candida albicans—An Overview

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
The selective, single‐targeting antifungal agents serve as the parent molecule(s) for the design of dual‐targeting, hybrid fungicidal agents and are discussed and compared, which enables the researchers to understand the logic for designing multi‐targeting new chemical entities (NCEs) that can exhibit dual‐sword attack on Candida albicans. ABSTRACT Due
Sarmistha Pal, Sriparna Pusti, Iftakhar Hussain Ansari, Sanchita Pradhan, Hritabrata Bhattacharya, Shuvradip Das   +5 more
wiley   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR‐T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT The tumour microenvironment (TME) of relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients is associated with resistance of DLBCL cells to CD19 CAR‐T cells. How to improve TME in DLBCL and improve the efficacy of CAR‐T cell therapy remains to be further explored.
Yao Qi, Xuemei Fan, Jia Wang, Xin Li, Juan Mu, Rui Cui, Qi Deng   +6 more
wiley   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +1 more source

Probing 5‐Nitroimidazole‐Triazole Hybrids as Potential Anti‐Kinetoplastid Agents: Synthesis and In Vitro Efficacy

ChemMedChem, Volume 21, Issue 13, 14 July 2026.
A series of 5‐nitroimidazole‐1,2,3‐triazole hybrids was synthesised and evaluated for antitrypanosomatid activity to assess their potential as treatments against leishmaniasis and trypanosomiasis. No notable in vitro activity against Leishmania was detected.
Liandi Ferreira, Gideon D. Badenhorst, Janine Aucamp, Keisuke Suganuma, David D. N’Da   +4 more
wiley   +1 more source

Optimizing Clinical Study Designs for CAR‐T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
ABSTRACT CAR‐T cell therapy is a cellular cancer immunotherapy that has impressively improved outcomes in hematological malignancies compared to conventional treatments. Yet, many patients do not respond permanently. Nonlinear mixed‐effects modeling can support a better understanding of the unique and not fully understood dose‐exposure and exposure ...
Fenja Klima, Anna M. Mc Laughlin, Robin Michelet, Wilhelm Huisinga, Katy Haussmann, Annette Künkele, Andrew C. Hooker, Charlotte Kloft   +7 more
wiley   +1 more source

ISSP Study Monitoring 2000: report to the ISSP General Assembly on monitoring work undertaken for the ISSP by ZUMA, Germany [PDF]

, 2003
Die ISSP-Codebücher schließen Untersuchungsbeschreibungen ein, die grundlegende Informationen über den Datensatz jedes Mitglieds vermitteln. Seit 1995 gibt es darüber hinaus eine detaillierte Forschungsdokumentation zu den einzelnen Untersuchungen.
Harkness, Janet, Klein, Sabine
core